Upstream Bio announces Phase 3 plans for verekitug in severe asthma and CRSwNP

Upstream Bio, Inc.

Phase 3: 400mg verekitug SC every 12 weeks vs placebo; one trial each in severe asthma and CRSwNP.
~1,500 patients total across both trials; broad populations, no biomarker restriction.
Primary endpoints: asthma AAER over 48 weeks; CRSwNP co-primary NPS and NCS at 48 weeks.
Trials to start Q1 2027; BLA submission expected with supportive results; potential launch as early as 2030.
Based on productive End-of-Phase 2 FDA meetings; data from 500+ treated patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.